Taro Pharmaceutical’s merger agreement with Sun Pharmaceutical was approved by the affirmative vote of Taro shareholders at an Extraordinary General Meeting and an Ordinary Class Meeting. Upon completion of the merger, currently expected to close in approximately 35 days, Taro will become a privately held company wholly owned by Sun Pharma and soon after its shares will be de-listed from the NYSE.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TARO: